molecules of the month


CRBN-based selective IKZF1/3 degrader

oral efficacy in lenalidomide-resist. xenograft

from phenotypic screen and optimization

J. Med. Chem., Mar. 4, 2020

Celgene, San Diego, CA

Structure of compound CC-92480
1 min read

CC-92480 (Celgene/Bristol Myers Squibb (BMS) oral in vivo CRBN-based selective IKZF1/3 degrader)

request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.

already a member? log in: